Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Lilly and Sigilon Therapeutics to develop encapsulated cell therapy for type 1 diabetes

Sigilon’s polymer encapsulation is based on the research of MIT scientists Daniel Anderson and Robert Langer

by Ryan Cross
April 9, 2018 | APPEARED IN VOLUME 96, ISSUE 15

Credit: Nature Medicine
Cryo-SEM image of alginate-based hydrogel used by Anderson, Langer, and colleagues to encapsulate human beta cells.

Eli Lilly & Co. is partnering with Cambridge, Mass.-based Sigilon Therapeutics to develop encapsulated cell therapies for patients with type 1 diabetes. Sigilon will receive $63 million up front, an undisclosed equity investment from Lilly, and up to $410 million in milestone payments.

Sigilon was founded in 2016 to make cell therapies that secrete proteins like antibodies, enzymes, and insulin in the body without causing a fibrotic immune response. The response, which immobilizes implanted cells, has stymied many previous attempts at cell therapy.

Sigilon says it overcomes the response by coating its cells with a polymer called Afibromer, based on the research of scientific cofounders and MIT scientists Daniel Anderson and Robert Langer. The firm announced raising $23.5 million in series A funding in June 2017.

In collaborating with Lilly, Sigilon will make Afibromer-encapsulated pancreatic beta cells—which are damaged or missing in type 1 diabetes patients—to be implanted in the body for prolonged insulin production.

In 2016, Anderson, Langer, and colleagues demonstrated the technique’s potential in diabetic mice. The team first coated human beta cells in an algae-derived alginate polymer that was chemically modified with triazole-thiomorpholine dioxide. The result was a porous biomaterial that lets molecules like insulin flow in and out but blocks the fibrotic immune response (Nat. Med. 2016, DOI: 10.1038/nm.4030).

The cells consistently controlled the animal’s glucose levels for the six months they were implanted.

The Lilly-Sigilon collaboration is unusual because most cell therapies are in development for cancer. Sigilon is also pursuing therapies for blood disorders and lysosomal storage disorders.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment